PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancerAntonino Glaviano, Alan Prem Kumar, Aaron Song Chuan Foo et al.|Molecular Cancer|2023Cited by 1.9k
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trialBirgit Geoerger, Navin Pinto, Margaret E. Macy et al.|The Lancet Oncology|2019Cited by 341
Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumorsBirgit Geoerger, G. Vassal|Neuro-Oncology|2010Cited by 159
The selective VEGFR1‐3 inhibitor axitinib (AG‐013736) shows antitumor activity in human neuroblastoma xenograftsJochen Rößler, Birgit Geoerger|International Journal of Cancer|2010Cited by 61
Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy ModelsEstelle Daudigeos‐Dubus, Birgit Geoerger|PLoS ONE|2015Cited by 57